TY - JOUR
T1 - Novel epicardial off-pump device for mitral regurgitation
T2 - acute evaluation
AU - Takaseya, Tohru
AU - Shiose, Akira
AU - Saraiva, Roberto M.
AU - Fumoto, Hideyuki
AU - Arakawa, Yoko
AU - Juravic, Mark
AU - Lombardi, Pierluca
AU - Fukamachi, Kiyotaka
N1 - Funding Information:
§Presented at the 23rd Annual Meeting of the European Association for Cardio-thoracic Surgery, Vienna, Austria, October 18—21, 2009. §§ This study was financially supported by MAQUET Cardiovascular LLC (San Jose, CA; a division of Getinge AB of Sweden). * Corresponding author. Address: Department of Biomedical Engineering/ ND20, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. Tel.: +1 216 445 9344; fax: +1 216 444 9198. E-mail address: fukamak@ccf.org (K. Fukamachi). 1 Mark Juravic and Pierluca Lombardi are employees of MAQUET Cardiovascular LLC.
PY - 2010/6
Y1 - 2010/6
N2 - Objective: This study evaluates the ability of a novel epicardial annuloplasty device Mitral Touch (MAQUET Cardiovascular LLC, San Jose, CA, USA) to reduce functional mitral regurgitation (MR) in a rapid ventricular pacing-induced dilated cardiomyopathy model in dogs. Methods: A median sternotomy was performed in 13 dogs after MR induction by rapid ventricular pacing (230 beats/min for an average of 35.6 ± 12.8 days). Two-dimensional epicardial echocardiographic and haemodynamic measurements were performed to evaluate the baseline MR grade, the septal-lateral (S-L) dimension of the mitral annulus, mitral valve (MV) geometry and left ventricular function. The Mitral Touch was implanted by sliding the anterior arm onto the floor of the transverse sinus and positioning the posterior arm just apical to the atrioventricular groove on the left ventricular posterolateral wall. The 24-mm-long device was implanted in eight dogs, the 27-mm-long device in four and the 30-mm standard length device in one. MR grade, S-L dimension and haemodynamics data acquisition were immediately rechecked after device implantation. Results: All implantations, which took only approximately 30 s to deploy, were performed on beating hearts without cardiopulmonary bypass. In one early case, after extended manipulation with undersized devices, an atrial laceration was created and bleeding occurred. Design changes were made to eliminate this complication. The MR grade was significantly (p = 0.003) reduced from 3.1 ± 1.1 at baseline to 1.4 ± 0.8 after device implantation. The S-L dimension at end of systole was also significantly (p = 0.001) reduced from 2.7 ± 0.4 cm at baseline to 2.3 ± 0.3 cm after device implantation (% reduction: 15.1 ± 10.6%). The mitral valve coaptation length was significantly (p = 0.0001) increased from 0.36 ± 0.11 cm to 0.50 ± 0.08 cm, and the mitral valve tethering area was significantly (p = 0.0003) decreased from 1.36 ± 0.38 cm2 to 0.81 ± 0.29 cm2 after Mitral Touch implantation. Conclusions: This new epicardial device was effective in significantly reducing MR and S-L dimensions acutely on the beating heart without requiring the use of cardiopulmonary bypass. Further studies are necessary to confirm the long-term maintenance of MR and S-L reductions.
AB - Objective: This study evaluates the ability of a novel epicardial annuloplasty device Mitral Touch (MAQUET Cardiovascular LLC, San Jose, CA, USA) to reduce functional mitral regurgitation (MR) in a rapid ventricular pacing-induced dilated cardiomyopathy model in dogs. Methods: A median sternotomy was performed in 13 dogs after MR induction by rapid ventricular pacing (230 beats/min for an average of 35.6 ± 12.8 days). Two-dimensional epicardial echocardiographic and haemodynamic measurements were performed to evaluate the baseline MR grade, the septal-lateral (S-L) dimension of the mitral annulus, mitral valve (MV) geometry and left ventricular function. The Mitral Touch was implanted by sliding the anterior arm onto the floor of the transverse sinus and positioning the posterior arm just apical to the atrioventricular groove on the left ventricular posterolateral wall. The 24-mm-long device was implanted in eight dogs, the 27-mm-long device in four and the 30-mm standard length device in one. MR grade, S-L dimension and haemodynamics data acquisition were immediately rechecked after device implantation. Results: All implantations, which took only approximately 30 s to deploy, were performed on beating hearts without cardiopulmonary bypass. In one early case, after extended manipulation with undersized devices, an atrial laceration was created and bleeding occurred. Design changes were made to eliminate this complication. The MR grade was significantly (p = 0.003) reduced from 3.1 ± 1.1 at baseline to 1.4 ± 0.8 after device implantation. The S-L dimension at end of systole was also significantly (p = 0.001) reduced from 2.7 ± 0.4 cm at baseline to 2.3 ± 0.3 cm after device implantation (% reduction: 15.1 ± 10.6%). The mitral valve coaptation length was significantly (p = 0.0001) increased from 0.36 ± 0.11 cm to 0.50 ± 0.08 cm, and the mitral valve tethering area was significantly (p = 0.0003) decreased from 1.36 ± 0.38 cm2 to 0.81 ± 0.29 cm2 after Mitral Touch implantation. Conclusions: This new epicardial device was effective in significantly reducing MR and S-L dimensions acutely on the beating heart without requiring the use of cardiopulmonary bypass. Further studies are necessary to confirm the long-term maintenance of MR and S-L reductions.
UR - http://www.scopus.com/inward/record.url?scp=77952585496&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952585496&partnerID=8YFLogxK
U2 - 10.1016/j.ejcts.2009.11.054
DO - 10.1016/j.ejcts.2009.11.054
M3 - Article
C2 - 20137971
AN - SCOPUS:77952585496
SN - 1010-7940
VL - 37
SP - 1291
EP - 1296
JO - European Journal of Cardio-thoracic Surgery
JF - European Journal of Cardio-thoracic Surgery
IS - 6
ER -